同源重组
卵巢癌
聚合酶
同源染色体
协调
聚ADP核糖聚合酶
医学
癌症
肿瘤科
奥拉帕尼
内科学
癌症研究
妇科
生物
药理学
遗传学
DNA
基因
物理
声学
作者
Cristin Roma,Riziero Esposito Abate,Alessandra Sacco,Daniela Califano,Laura Arenare,Francesca Bergantino,Carmela Pisano,Sabrina Chiara Cecere,Giovanni Scambia,Domenica Lorusso,Grazia Artioli,Giulia Tasca,Anna Spina,Daniela Russo,Angiolo Gadducci,Carmine De Angelis,Alessandra Bologna,Sergio Marchini,Ettore Capoluongo,Federica Perrone,Sandro Pignata,Nicola Normanno
标识
DOI：10.1016/j.ejca.2024.114127
摘要
Homologous Recombination Deficiency (HRD) status predicts response to treatment with poly(ADP-ribose) polymerase inhibitors in Ovarian Cancer (OC) patients. The Myriad myChoiceCDx Assay is approved by Food and Drug Agency for the HRD assessment. Here we compared the HRD status obtained by three commercial panels with the results from Myriad reference test.
科研通智能强力驱动
Strongly Powered by AbleSci AI
cocolu
爱静静
Polymer72
带头大哥
VDC
QDU
mhl11
乐乐乐乐乐乐
tuanheqi
HEIKU
嗯哼
pluto
hhhblabla
子车茗
luoshi
加菲丰丰
iNk
Yoanna_UTHSC
Jack80
彭于彦祖
皖公网安备34019202002308
